Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lisata Therapeutics (LSTA) Research & Development (2016 - 2025)

Lisata Therapeutics' Research & Development history spans 13 years, with the latest figure at $1.1 million for Q4 2025.

  • For Q4 2025, Research & Development fell 61.56% year-over-year to $1.1 million; the TTM value through Dec 2025 reached $7.9 million, down 29.87%, while the annual FY2025 figure was $7.9 million, 29.87% down from the prior year.
  • Research & Development reached $1.1 million in Q4 2025 per LSTA's latest filing, down from $2.0 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $3.4 million in Q3 2023 to a low of $1.1 million in Q4 2025.
  • Average Research & Development over 3 years is $2.7 million, with a median of $2.8 million recorded in 2024.
  • Peak YoY movement for Research & Development: increased 1.95% in 2024, then tumbled 61.56% in 2025.
  • A 3-year view of Research & Development shows it stood at $3.0 million in 2023, then dropped by 2.09% to $2.9 million in 2024, then crashed by 61.56% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Research & Development are $1.1 million (Q4 2025), $2.0 million (Q3 2025), and $2.3 million (Q2 2025).